Clinical

Dataset Information

0

Randomized study of the detection of mutations by BEAMing technology in advance of the radiological diagnosis of progression in patients with metastatic colorectal cancer and primary tumor in the left colon / rectum


ABSTRACT: Primary objectives: Median of the progression-free survival of patients with mCRC who maintains the treatment in conventional 1st line, QT + anti-EFGR, versus patients who withdraw anti-EGFR therapy after detection of mutations of the RAS gene / BRAF through the OncoBEAM test.

DISEASE(S): Comparar La Mediana De Supervivencia Libre De Progresión De Pacientes Con Ccrm Que Mantienen El Tratamiento En 1º Línea Convencional, Qt + Anti-efgr, Frente A La De Los Pacientes A Los Que Se Retira La Terapia Anti-egfr Tras La Detección De Mutaciones Del Gen Ras/braf Mediante El Test Oncobeam™.,Colorectal Cancer,Median Of The Progression-free Survival Of Patients With Mcrc Who Maintains The Treatment In Conventional 1st Line, Qt + Anti-efgr, Versus Patients Who Withdraw Anti-egfr Therapy After Detection Of Mutations Of The Ras Gene / Braf Through The Oncobeam ™ Test.

PROVIDER: 2538676 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| S-EPMC7778859 | biostudies-literature
| S-EPMC7235657 | biostudies-literature
| S-EPMC3606662 | biostudies-literature
| S-EPMC6122183 | biostudies-other
| S-EPMC4489954 | biostudies-literature
| S-EPMC8283508 | biostudies-literature
| S-EPMC5135162 | biostudies-other
| S-EPMC4829965 | biostudies-literature
2021-07-23 | PXD025237 | Pride
| PRJEB45201 | ENA